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Abstract: Recent progress in nanotechnology has triggered the site speciﬁ  c drug/gene delivery 
research and gained wide acknowledgment in contemporary DNA therapeutics. Amongst 
various organs, liver plays a crucial role in various body functions and in addition, the site is 
a primary location of metastatic tumor growth. In past few years, a plethora of nano-vectors 
have been developed and investigated to target liver associated cells through receptor mediated 
endocytosis. This emerging paradigm in cellular drug/gene delivery provides promising approach 
to eradicate genetic as well as acquired diseases affecting the liver. The present review provides 
a comprehensive overview of potential of various delivery systems, viz., lipoplexes, liposomes, 
polyplexes, nanoparticles and so forth to selectively relocate foreign therapeutic DNA into liver 
speciﬁ  c cell type via the receptor mediated endocytosis. Various receptors like asialoglycoprotein 
receptors (ASGP-R) provide unique opportunity to target liver parenchymal cells. The results 
obtained so far reveal tremendous promise and offer enormous options to develop novel DNA-
based pharmaceuticals for liver disorders in near future.
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Introduction
The prospects of gene therapy on the future of modern molecular medicine hold a great 
promise for alleviation or cure from many untreatable diseases. However, the lack 
of efﬁ  cient site speciﬁ  c delivery systems obscured the introduction of gene medicine 
in clinical practice and therefore, the potential of gene therapy has not been realized 
completely. Ideally, a gene delivery system should be stable, biocompatible, nontoxic, 
cost effective and capable to transfer exogenous highly anionic genetic materials 
(ie, DNAs, antisense oligonucleotides [AS-ODNs], short interfering RNAs [siRNAs]) 
into tissue speciﬁ  c site. Viral vectors (ie, adenovirus, retrovirus) have been extensively 
investigated and demonstrated efﬁ  cient hepatocytes transfection efﬁ  ciency even 
relevant to clinically acceptable level (Wu et al 1998). Their clinical applications are 
hindered due to safety considerations (Crystal 1995; Felgner et al 1997; Hacein-Bey-
Abina et al 2003). Moreover, last three decades have seen tremendous developments 
in various nonviral synthetic delivery systems like liposomes, nanoparticles, lipoplexes 
and polyplexes for genes and oligonucleotides (ODNs) A number of cationic 
polymers have also been reported to execute efﬁ  cient gene transfection including 
polyethylenimine (PEI), polyallylamine (PAA), poly-L-lysine (PLL), chitosan, etc 
(Elouahabi and Ruysschaert 2005; Park et al 2006; Pathak et al 2007).
A major goal of gene therapy is to obtain targeted vectors that transfer genes 
efﬁ  ciently to speciﬁ  c cell types. The liver possesses a variety of characteristics (its 
large size, central role in metabolism, accessibility to large molecules and secretion of 
serum proteins) that make this organ very attractive for gene therapy. The liver plays 
a pivotal role in the metabolism and more importantly as protein factory for serum 
circulating polypeptides (ie, coagulation factors) and various enzymes. Being a very International Journal of Nanomedicine 2008:3(1) 32
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large organ (cells in humans), the liver serves as a major 
protein and lipid cell production site. At the same time, it is 
a partial “immuno-privilege” site that tolerates all potential 
immunological reactions against gastrointestinal tract (GIT) 
invaders entering it through the portal system. Mainly, liver 
is composed of various cell types including hepatocytes 
(liver parenchymal cells), sinusoidal endothelial cells and 
kuffer cells (resident liver macrophages). Hepatocytes are 
the predominant cell type in the liver. In many of the genetic 
disorders such as ornithine transcarbamylase deﬁ  ciency, 
hepatocytes are the prime target to transfer genes. Approxi-
mately, 80% of the liver mass is made of these cells. The 
hepatocytes are round in shape containing a nucleus and an 
abundance of cellular organelles (ie, endoplasmic reticulum 
and golgi apparatus) associated with metabolic and secretary 
functions. Also there are high numbers of mitochondria to 
provide energy to support the many metabolic functions of 
liver. Some of the hepatocytes lie adjacent to endothelial 
cells, which form the walls of the sinusoids. These two 
cell types are separated by small space called the space 
of Disse (Figure 1). The liver is blood rich organ, and its 
role is coupled with circulating blood (ie, distribution of 
gene products from liver to systemic circulation). This 
makes parenchymal liver cells the attractive proposition 
for gene delivery and thus for the treatment of variety of 
liver associated diseases (ie, Wilson’s disease, hereditary 
hemochromatosis, α1-antitrypsin deﬁ  ciency). For instance, 
genetic defects of hepatocytes also play vital role in α1-
antitrypsin deﬁ  ciency, hemophilia and lipoprotein receptor 
deﬁ  ciency (Wu et al 1998). Hepatocellular carcinoma (HCC) 
is the most common primary liver malignancy with a rising 
incidence worldwide. In addition to primary tumors, the liver 
is the most common organ where tumor metastases occur. 
Both unresectable HCC and liver metastases of digestive 
tumors lack effective therapy and new therapeutic modalities 
are needed. Hepatocytes uniquely express asialoglycopro-
tein receptors (ASGP-R) on their sinusoidal surface and 
therefore, asialoglycoproteins or galactosylated polymers 
have been used to deliver variety of pharmaceutical agents 
(ie, antitumor drugs, genes). This review focuses on various 
facets and motifs associated with ASGP-R mediated gene 
delivery to target liver hepatocytes.
Asialoglycoprotein or galactose-
speciﬁ  c receptors as molecular 
porch
Targeting to liver parenchymal cells is feasible due to the 
abundance of ASGP-R or hepatic lectins on parenchymal 
Figure 1 Schematic representation of hepatocytes.
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hepatocytes (Stockert 1995), which contain 105 −5 × 105 
binding sites per cell. These surface receptors are randomly 
distributed over the sinusoidal (basolateral) plasma membrane 
domain facing the capillaries and are found in coated pits and 
uncoated vesicles together with the mannose-6-phosphate, 
transferrin and poly(Ig) receptors, but they are essentially 
absent from the apical membrane facing the bile canaliculi 
(Wall and Hubbard 1981; Geuze et al 1982; Matsuura et al 
1982). The human ASGP-R contains two subunits, H1 and 
H2. The human ASGP-Rs are hetero-oligomeric complexes 
consisting of H1 and H2 subunits in the ratio of 5:1. The major 
subunit, H1, exclusively contains the signal for endocytosis, 
while H2 contributes an important element to basolateral 
sorting of the hetero-oligomeric receptor molecules (Fuhrer 
et al 1994). Further, ASGP-R may play a role in the 
pathogenesis of autoimmune chronic liver diseases.
Naturally, ASGP-R is a prototype of the class of receptors 
that constitutively enters the cells by recognizing glycopro-
teins bearing terminal galactose or N-acetyl glucosamine 
residues via clathrin coated pits and delivers ligand to these 
intracellular compartments (Stockert 1995). This speciﬁ  c 
uptake mechanism can be activated by coupling appropriate 
glycoproteins, lactose or galactose to synthetic substances. 
Extravasation of delivery systems through the vascular walls 
is a major obstacle in systemic gene delivery. Sinusoidal 
wall of the liver lacks a basement membrane and possesses 
a fenestrated (∼100 nm) endothelium. Therefore, for efﬁ  cient 
internalization, systems/ polyplexes should be small enough 
to pass through the fenestrae and get into the space of Disse 
which is in direct contact with hepatocytes. Endogenous 
glycoproteins, from which sialic acid has been removed by 
the action of sialidases, bind tightly to the ASGP-R, which 
are located on hepatocyte plasma membranes. After inter-
nalization by adsorptive endocytosis, they are delivered to 
lysosomes for degradation. Lysosome is always accepted 
as the end point of the endocytic pathway mediated by 
ASGP-R, where ligand was degraded to constituent amino 
acids and sugars. Therefore, receptor-mediated clearance of 
ASGP-R is an important aspect of the turnover of plasma 
glycoproteins. They are elevated in serum of patients with 
hepatic cirrhosis or hepatitis. Therefore, in addition to being 
a model of receptor-mediated endocytosis, the presence of 
the receptors on hepatocytes provides a membrane-bound 
active site for cell-to-cell interactions for selective targeting 
of foreign genes.
Several ligands like asialo-feutin, asialo-transferrin, 
asialo-ceruloplasmin, asialo-lactoferrin, asialo-orosomucoid, 
lac-BSA, hepatoglobulin, antibodies and galactose have 
been exploited for cell selective transgene expresion both 
in vivo and in vitro (Nishikawa and Huang 2001; Arangoa 
et al 2003). Of these ligands, galactose is the most exten-
sively studied ligand that is recognized by ASGP-R on liver 
hepatocytes.
Delivery strategies
In order to exhibit effective pharmacologic response, 
nucleic acid bioactives must enter the cells and achieve the 
appropriate concentration in the intracellular compartment. 
Basically, cellular uptake refers to binding of nucleic acid to 
the phospholipid bilayers membrane and their ingestion by 
cell (release into cytoplasm or nucleus). After the binding 
of nucleic acid to cell-surface protein, internalization into 
endocytic compartment occurs. The phospholipid bilayers 
represent major impediment to the moments of ions or mol-
ecules. The internalization of naked nucleic acid is gener-
ally inefﬁ  cient, because of their negative charge, only few 
DNA copies actually diffuse in to the similarly negatively 
charged cell membranes. This electrostatic repulsion lowers 
the intracellular uptake of DNA, which makes DNA more 
prone to nuclease attack.
The strategies that have been adopted to improve the 
uptake of various nucleic acid based therapeutic agents, are 
microinjection, passive diffusion, endocytosis (ie, receptor 
mediated endocytosis, ﬂ  uid phase pinocytosis, adsorptive 
endocytosis), and artiﬁ  cially enhanced uptake (ie, using 
delivery vectors like liposomes, micro- or nanoparticles 
or dendrimers) (Akhtar et al 2000). Endocytosis mecha-
nism falls into two broad classes, phagocytosis (cell eating 
phenomenon) and pinocytosis (cell drinking phenomenon). 
In this process, DNA is engulfed, followed by sequential 
inward folding of the plasma membrane (invagination), 
enveloping a droplet of extracellular media, pinching off the 
membrane and formation of an intracellular coated vesicle 
containing the ingested material (endosome formation). 
These coated vesicles or endosomes increase their size by 
fusing with each other by hemolytic fusion. Most endosomes 
fuse with primary lysosomes (which contains large amount 
of hydrolytic enzymes) to form secondary lysosomes, which 
are the ﬁ  nal destination of internalized macromolecules 
targeted for degradation. While the ingested material is rap-
idly broken down by the lysosomal enzymes, the endocytic 
membranes are returned to the plasma membrane. Some 
endosomes bypass the lysosomes, and traverse the cytoplasm 
(transcytosis). Macromolecules are generally internalize into 
the cell by endocytosis and this method is limited to only 
mammalian cells. Pinocytosis, another form of endocytosis, International Journal of Nanomedicine 2008:3(1) 34
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involves macropinocytosis (1 µm), clathrin-mediated 
endocytosis (∼120 nm), caveolin-mediated endocytosis 
(∼60 nm), and clathrin- and caveolae-dependent endocy-
tosis (∼90 nm). In internalization process, particles are 
taken up by cells after splitting them into smaller particles. 
Conner and Schmid (2003) elegantly demonstrated multiple 
portal of entry into the mammalian cells. Furthermore, vari-
ous drug delivery technologies (ie, adenovirus, liposome, 
nanoparticles, etc) have been developed to efﬁ  ciently trans-
fer therapeutic material inside the cell. The detailed reports 
on these nano-vectors can be found elsewhere (Azzam and 
Domb 2004; Elouahabi and Ruysschaert 2005; Park et al 
2006). Figure 2 shows schematic representation of receptor 
mediated endocytosis.
Lipid based devices for hepatocyte 
speciﬁ  c gene delivery
Liposomes are considered to be a mainstream gene/drug 
delivery technology. It is believed that small liposomes with 
diameters below 100 nm have relatively easy access to the 
transendothelially located hepatocytes (presence of numerous 
open fenestrations in the endothelial lining of the sinusoids, 
which have an average diameter of approximately 150 nm) 
without using any targeting ligand. However, liposomes with 
diameters even higher than those of the endothelial fenestrations 
may gain access to the hepatocytes in large quantities, 
depending on their lipid compositions. Applying cell-speciﬁ  c 
targeting technology to liposomes would further improve the 
gene delivery efﬁ  ciency and reduce any unexpected side effects. 
As discussed earlier, various ligands have been investigated 
for their bio-signaling and bio-sensing potential to target liver 
parenchymal cells. Galacotose is the most explored ligand 
for liver speciﬁ  c gene transfer. Liposomes are glycosylated 
by introducing glycoproteins or synthetic glycolipids. Some 
reviews discussed the glycosylated liposomes for cell-selective 
gene delivery in detail (Hasida et al 2001; Kawakami et al 
2002; Nishikawa et al 2003). Several research groups have 
attempted to actively target glycosylated liposomes to the 
hepatocytes by exploiting the asialoglycoprotein receptors 
both in vitro and in vivo. Shimada and coworkers (1997) 
synthesized biodegradable poly(ethyleneglycol) (PEG)-
coupled galactolipids, in which the galactose moiety was 
separated from a diacylglyceride lipid interface by a PEG 
chain of variable lengths (PEG 10/20/40). The system was 
designed to exploit the anti-opsonic action and the spacer 
effect of the PEG chains, to improve the exposure of the 
galactose moiety and to provide an optimal conﬁ  guration 
for interactions with the hepatocyte galactose receptors. 
The proposed liposomes, Gal-PEG10-Lip, got cleared 
rapidly from plasma with a half-life (t1/2) of 30 min. 
whereas, identical sized and control liposomes without 
the Gal-PEG10-Lip had a t1/2 of approximately 12 h. In 
this study, they found that the rapid plasma elimination of 
the Gal-PEG10-Lip liposomes could be attributed entirely 
to increased uptake by the kuffer cells of liver (90% of 
injected dose). Whereas, the uptake by the spleen was found 
to be decreased (1% of injected dose). Further, it was 
observed that a single injection of N-acetylgalactosamine 
one min prior to administration of Gal-PEG-Lip liposomes 
reduced the initial rate of plasma clearance to control 
levels. However, the incorporation of monomethoxypo
ly(ethyleneglycol)-distearoylphosphatidylethanolamine 
(PEG-DSPE) in the Gal-PEG10-Lip liposomes partially 
reversed the effect of the galactolipid with respect to liver 
and spleen uptake. Thus, the observation suggests that 
the ligands recognized by the galactose  receptors on the 
kuffer cells and transfer the content to these cells instead 
of hepatocytes.
Some novel galactosylated cholesterol derivatives, 
cholesten-5-yloxy-N-(4-((1-imino-c-b- D-thiogalactosyl-
ethyl) amino) butyl) formamide (Gal-C4-Chol) and its ethyl 
formamide and hexyl formamide analogues (Gal-C2-Chol, 
Gal-C6-Chol), were synthesized to prepare liposomal 
gene carriers (Kawakami et al 1998). Systems possess 
sufficient charge to bind DNA and galactose residue 
for ASGP-Rs in hepatocyte. Liposomes, consisting of 
Gal-C4-Chol, 3β[N’N’N’dimethylaminoethane)-carbamoyl] 
cholesterol (DC-Chol), and dioleoylphosphatidylethanolamine 
(DOPE) in ratio of 3:3:4, showed higher transfection activity 
and [32P]DNA uptake than DC-Chol/DOPE (6:4) liposomes in 
HepG2 cells. These results indicated that the liposome/DNA 
complexes prepared using novel galactosylated cholesterol 
derivatives were efﬁ  ciently recognized by ASGP-Rs and 
internalized and led to the gene expression. Additionally, 
the galactosylated cholesterol derivative with a longer spacer 
showed higher transfection activity.
Kawakami and coworkers (2000) studied galactosylated 
cationic liposomes containing N-[1-(2,3-dioleyloxy)propyl]-
N,N,N-trimethylammonium chloride (DOTMA), Gal-C4-
Chol and Chol to elucidate the in vivo gene transfection in 
the liver via ASGP-R mediated endocytosis. A markedly 
higher gene expression in the liver was observed following 
intraportally injection of plasmid DNA that was complexed 
with DOTMA: Chol: Gal-C4-Chol (1:0.5:0.5) and DOTMA/
Gal-C4-Chol (1:1) liposomes. Results showed that the effect 
was one order of magnitude higher than naked DNA and International Journal of Nanomedicine 2008:3(1) 35
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Figure 2 Schematic representation of internalization of ligand anchored system with cell surface lectins.
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DOTMA: Chol (1:1) liposomes. While, prior exposure with 
galactosylated bovine serum albumin signiﬁ  cantly reduced 
the hepatic gene expression (Figure 3).
Another group of researchers proposed β-sitosterol-
D-glucoside (Sit-G)-containing liposomes/DNA complex 
(Sit-G-liposome/DNA complex) for liver specific gene 
targeting. Transfection efﬁ  ciency of the luciferase marker 
gene by Sit-G-liposome/DNA complex was found to be 
increased even in the presence of 10% serum in vitro, and was 
selectively high in the mouse liver reaching expression values 
up to an average of 14.9 pg luciferase/mg tissue protein, com-
pared with Tfx/DNA complex, which showed approximately 
three-fold higher gene expression than Sit-G-liposome/DNA 
complex in vitro (Figure 4) (Hwang 2001).
In order to accelerate endosomal exit of antisense acid 
drugs, Wang et al (2001) investigated the liposomal formula-
tion with pH-sensitive property to target hepatocytes. The pH 
sensitivity allows the liposome to escape from endosome/
lysosome at low pH value to release the entrapped AS-ODN 
in cytoplasm to take action. In their study, hepatocyte-tar-
geting and pH-sensitivity of liposome were analyzed by 
galactose-receptor competitive inhibition and hemolysis of 
chicken red blood cells. AS-ODNs, HCV363 against HCV 
5'NCR, was delivered via prepared liposome to transgenic 
HepG2 cells and evaluated for its inhibitory effect on lucif-
erase expression controlled by HCV 5'NCR in HepG2 using 
luciferase assay system. The results showed that different 
concentrations of galactose solutions reduced the delivery 
effects of liposomes to some extent. In another study using 
pH-sensitive liposomes, Wen and coworkers (2004) pro-
posed liposomes with four types of targeting molecules with 
galactose residue and pH-sensitive lipids DC-chol/DOPE 
with integrated property of hepatocyte speciﬁ  city and pH 
sensitivity. In their experiment, Liposome 18-gal showed 
desired hepatocyte speciﬁ  city, pH sensitivity, low cytotoxic-
ity, and high transfection efﬁ  ciency.
Scherphof and coworkers (2002) studied the mechanism 
of interaction of liposomes with hepatocytes, in particular, 
the involvement of plasma proteins and lipoprotein recep-
tors. Results showed remarkable differences in interac-
tions and uptake mechanism among differently composed 
liposomes. They observed that Apolipoprotein E (ApoE) 
strongly enhances uptake of neutral liposomes, while uptake 
of charged liposomes was barely inﬂ  uenced by this protein, 
despite a higher binding capacity. ApoH (2-glycoprotein I), 
on the other hand, binds strongly to negatively charged 
liposomes (30% PS), but appears to have little effect on 
in vitro uptake by various liver cells hepatocytes, kupffer 
cells or endothelial cells. A substantial fraction (in some 
cases 50%) of an injected dose of liposomes was taken up 
Figure 3 In vitro transfection activity of DNA/liposome complexes at a charge ratio of 2.3 in HepG2 cells. Cells were transfected with DNA/liposome complexes in the 
absence (†) and presence (†) of 20 mM galactose. DOPE containing liposome/DNA complexes (A) and DOPE noncontaining liposome/DNA complexes (B) were applied to 
the cells. DNA concentration was ﬁ  xed at 0.5 µg/ml in all experiments. Statistical analysis was performed by analysis of variance (**indicated p  0.01; NS, not signiﬁ  cant). Each 
value represents the mean 6 SD values (n = 3) (Adapted from Kawakami et al 2000).International Journal of Nanomedicine 2008:3(1) 37
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by the hepatocytes without the need for active targeting. In 
many cases, the attachment of (ga)lactosyl moieties on the 
liposomal surface causes an increase in uptake by the liver 
macrophages at the expense of the hepatocytes. Furthermore, 
Murao and coworkers (2002) investigated the effects of the 
lipid composition of galactosylated liposomes on their tar-
geted delivery to hepatocytes. They prepared several types of 
liposomes using distearoyl-L-phosphatidylcholine (DSPC), 
cholesterol (Chol) and cholesten-5-yloxy-N-(4-((1-imino-
2-D-thiogalactosylethyl)amino) butyl)formamide Gal-C4-
Chol), and labeled with [3H]cholesterol hexadecyl ether. 
Their tissue disposition was investigated in mice following 
intravenous injection. The [3H]D-SPC/Chol/Gal-C4-Chol 
(60:35:5) liposomes exhibited extensive hepatic uptake then 
[3H]DSPC/Chol (60:40) liposomes in HepG2 cells. Separa-
tion of the liver cells showed that galactosylated liposomes 
are preferentially taken up by hepatocytes, whereas those 
lacking Gal-C4-Chol distribute equally to hepatocytes and 
nonparenchymal cells (NPC). Increasing the molar ratio 
of DSPC to 90% resulted in enhanced NPC uptake of both 
liposomes, suggesting their uptake via a mechanism other 
than asialoglycoprotein receptors. DSPC/Chol/Gal-C4-Chol 
(60:35:5) and DSPC/Chol/Gal-C4-Chol (90:5:5) liposomes 
exhibited similar binding to the surface of HepG2 cells, but 
the former were taken up faster by the cells. In case of viral 
vectors, it has been known that intra-arterial administration is 
more efﬁ  cient than intravenous, though cationic lipid vectors 
have not been compared in this way, Choi and co-workers 
(2002) compared the efﬁ  ciency of intra-arterial, intraportal, 
and intravenous route to deliver cationic lipid emulsion/DNA 
complex in rat liver. It was found that the cationic lipid emul-
sion/DNA complex efﬁ  ciently transfected the various organs 
via the different routes of administration. Liver luciferase 
values were found signiﬁ  cantly higher in the intra-arterial 
or intraportal administered groups.
In another report, a novel lipidic vector, composed of 
DOTAP/Chol liposomes, asialofeutin (AF), protamine sulfate 
and DNA, has been shown to improve signiﬁ  cant levels of 
gene expression in HepG2 cells and in the liver upon i.v. 
administration. It was observed that, upon addition of free 
AF, the uptake by cells having ASGP-R on their plasma 
membrane was decreased, indicating that AF-lipoplexes 
were taken up speciﬁ  cally by cells via ASGP-R mediated 
endocytosis. Results obtained from transfections performed 
in ASGP-R negative cells, ie, HeLa cells, conﬁ  rmed this 
mechanism. Further, on addition of the condensing peptide, 
protamine sulfate, smaller complexes were obtained, which 
further enhanced the uptake of AF-complexes in HepG2 cells 
and in the liver (Arangoa et al 2003).
Fumoto and coworkers (2004) proposed, enhanced 
hepatocyte-selective in vivo gene expression by stabilized 
galactosylated liposome/plasmid DNA complex using 
sodium chloride for complex formation. They demonstrated 
that the presence of an essential amount of sodium chloride 
(NaCl) during the formation of cationic liposome/plasmid 
DNA complexes (lipoplexes) stabilizes the lipoplexes 
Figure 4 Biodistribution of gene expression 24 h after intravenous injection with plasmid DNA (50 µg) complexed with liposomes or Tfx into mice (Adapted from Hwang 
et al 2001).International Journal of Nanomedicine 2008:3(1) 38
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according to the surface charge regulation (SCR) theory. 
It was observed that upon intraportal administration, the 
galactosylated SCR lipoplexes (5 and 10 mM NaCl solution 
in lipoplex) resulted 10–20-fold higher hepatic transfection 
activity than that of galactosylated conventional lipoplexes 
in mice. The transfection activity in hepatocytes of galac-
tosylated SCR lipoplexes was signiﬁ  cantly higher than that 
of conventional lipoplexes, and pre-exposure to competitive 
asialoglycoprotein-receptor blocker signiﬁ  cantly reduced 
the hepatic gene expression, suggested that hepatocytes 
were responsible for high hepatic transgene expression of 
the galactosylated SCR lipoplexes.
Bartsch and coworkers (2004) proposed stabilized lipid 
coated lipoplexes for the delivery of AS-ODNs to liver 
endothelial cells in vitro and in vivo. In their study, the 
behavior of untargeted coated cationic lipoplexes (CCLs) 
was compared with CCLs that were targeted to scavenger 
receptors on liver endothelial cells by covalent coupling of the 
poly-anion aconitylated human serum albumin (Aco-HSA) 
to the particle surface. Sun and coworkers (2005) studied 
galactosylated liposome-polycation-DNA complexes 
(LPD) as potential gene carriers to cells. In their study, four 
cholesterylated thiogalactosides with different spacer length 
were synthesized to formulate novel lipid-polycation-DNA 
(LPD) complexes, which were composed of galactosylated 
cationic liposomes, protamine sulfate and plasmid DNA. 
The galactosylated LPD complexes signiﬁ  cantly improved 
the levels of gene expression in cultured hepatoma cells, 
HepG2 and SMMC-7721. Moreover, increased transfection 
activity was not observed in mouse ﬁ  broblasts L929 for 
galactosylated LPD. Cytotoxicity assay of galactosylated 
LPD complexes showed no toxicities to L929 cells and 
HepG2 cells.
Galactose density on liposomal surface also plays an 
important role in ASGP-R mediated uptake. Managit and 
coworkers (2005), prepared liposomes containing various 
molar ratios of cholesten-5-yloxy-N-(4-((1-imino-2-D-
thiogalactosylethyl)formamide (Gal-C4-Chol) as a ligand 
for asialoglycoprotein receptors to study the effect of the 
galactose content of Gal-liposomes. They observed that 
after i.v. injection, Gal-liposomes having Gal-C4-Chol of 
3.5%, 5.0%, and 7.5%, rapidly disappeared from the blood 
and exhibited rapid liver accumulation with up to ∼80% of 
the dose within 10 min, whereas Gal-liposomes having low 
Gal-C4-Chol (1.0% and 2.5%) showed a slight improvement 
in liver accumulation compared with bare-liposomes. Gal 
liposomes with high Gal-C4-Chol were preferentially 
taken up by hepatocytes and the highest uptake ratio by 
parenchymal cells to nonparenchymal cells was observed 
with Gal-liposomes having of 5.0% Gal-C4-Chol.
Recently, Wong and coworkers (2006) reported 
a versatile T7 phage tail fiber (p17) peptide to target 
proteins, polymers, siRNA and also particles such as DNA 
polyplexes and liposomes to hepatocytes. This peptide 
possesses 33 amino acid sequence within the p17 coiled-coil 
rod domain. The ability of this hepatocyte-targeting peptide 
to target DNA-containing particles suggests that it can be 
useful in the development of both nonviral and viral vectors. 
Delivery of ODNs to speciﬁ  c cells and maintenance of their 
biological functions are important for nucleic acid therapy. 
C-myc AS-ODNs are effective to suppress proliferation of 
human hepatocellular carcinoma and tumor growth of mice 
hepatoma model. Serum proteins impose severe barrier in 
gene delivery. Serum contains anionic compounds that 
quite often complex with positively charged transfection 
reagents, resulting in reduced transfection (Ghosh et al 
2000). In order to transfer gene even in presence of high 
concentration of serum, Garcia and coworkers (2007) 
explored serum-resistant lipopolyplexes by employing PEI 
(800, 25, and 22kDa) and DOTAP and cholesterol, for gene 
delivery speciﬁ  cally to liver tumor cells. All vectors were 
found to be highly effective to protect DNA from DNAse 
I attack and transfer DNA efﬁ  ciently to liver tumor cells. 
Among all developed systems, complexes formed with 
linear PEI (22 kDa) were shown to be more effective and 
efﬁ  cient than conventional lipopolyplexes and polyplexes. 
The similar trend was observed in the presence of the 
therapeutic gene pCMVIL-12, while keeping cell viability 
more than 80%.
Bondi and coworkers (2007) proposed novel cationic 
solid-lipid nanoparticles (SLN) as nonviral vectors for gene 
delivery into liver cancer cells. Cationic SLN were able to 
form stable complexes with DNA and to protect it from 
DNase I digestion. In vitro studies shows that both SLN and 
SLN-DNA complexes exhibited a low degree of toxicity on 
human liver cancer cells. Further, SLN-DNA complexes were 
able to promote transfection of liver cancer cells.
Thus, the most signiﬁ  cant biological consequence of 
modiﬁ  cation of liposomes with galactose moiety is resulted 
in sharp increase in gene delivery efﬁ  ciency in hepatocytes 
cells by virtue of ASGP-Rs. Gene transfer facilitated by these 
receptors is carried out by high afﬁ  nity interaction between 
galactose ligand and respective receptors on the surface of 
liver parenchymal cells. Optimization of the co-lipid type of 
cationic liposomes, the charge ratio of the liposome – DNA 
complexes, ligand density and some physicochemical International Journal of Nanomedicine 2008:3(1) 39
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considerations will lead to further improvements in hepatic 
gene delivery using glycosylated liposomes.
Polycation mediated liver speciﬁ  c gene 
targeting
Poly-L-lysine
Poly-L-lysine (PLL) is a cationic, biocompatible and 
biodegradable polymer consists of only primary amines, 
which allow easy chemical modiﬁ  cations. Further, PLL can 
be substituted with targeting moiety to speciﬁ  cally target 
hepatoma cells. Lactoferrin (LF) is a globular multifunctional 
protein with antimicrobial activity and belongs to the 
transferrin family of nonheme iron binding glycoprotein. LF 
was used as a speciﬁ  c ligand for gene delivery to hepatocytes. 
In one such experiment, bovine lactoferrin and human 
lactoferrin were conjugated to PLL using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC). Results showed 
that the Lf/pL conjugates prepared by this method efﬁ  ciently 
transferred the reporter genes, CAT and LacZ genes, to 
HeLa and hepatic cells. The bovine lactoferrin (bLf)/pL 
and human lactoferrin (hLf)/pL conjugates could transfer 
the reporter genes to various hepatocytes including primary 
mouse hepatocyte, Hepa 1-6, SK-Hep1 and Chang liver, but 
not to NIH 3T3 mouse ﬁ  broblast cells, indicating that the 
Lf/pL conjugates conferred hepatocyte-speciﬁ  c gene transfer 
(Oh et al 1997).
Yang and coworkers (2000) compared the effects of 
liposomes and glyco-poly(L-lysine) (GLL) on liver targeted 
uptake and expression of plasmid in rat liver. In this study, 
they found that expression of plasmid mediated by both lipo-
some and GLL decreased within a week. Both carriers efﬁ  -
ciently delivered the plasmid, but GLL was found to be much 
better as compared to liposome concerning the distribution 
and plasmid expression in target organ liver. Hyaluronic acid 
(HA) is a nonsulfated glycosaminoglycan distributed widely 
throughout connective, epithelial, and neural tissues. It is 
one of the chief components of the extracellular matrix, con-
tributes signiﬁ  cantly to cell proliferation and migration, and 
may also be involved in the progression of some malignant 
tumors. Liver sinusoidal endothelial cells (SECs) possess 
unique receptors that recognize and internalize HA. Takei 
and coworkers (2004) proposed targeted gene delivery using 
hyauronate-grafted-PLL copolymer. In organ distribution of 
a 32P-radiolabeled plasmid (pSV β-galactosidase expression) 
complexed to PLL-g-HA, the complex was delivered to the 
liver. After 1 hour of injection, 93% of the injected counts 
was detected in the liver, while DNA, complexed to PLL, was 
distributed mostly in the lungs. These observations suggest 
that on decorating the PLL with ligands such as lactoferrin 
and galactose, efﬁ  cient gene carriers speciﬁ  c to hepatocytes 
can be engineered.
Polyethyleneimine
Among all polycations, polyethyleneimine (PEI) is found to 
be very efﬁ  cient due to its inherent proton sponge property. 
Various Gal-PEI (MW 1800, 10000, 70000) derivatives were 
synthesized and investigated their potential as a targetable 
vector to ASGP-R-positive cells. Transfection efﬁ  ciency was 
found highest with PEI (1800) in HepG2 cells (Morimoto et al 
2003). In another experiment, Kunath and coworkers (2003), 
proposed galactosylated PEI with broad range of degree of 
substitution (3.5%–31%) of all amino groups. Photon cor-
relation spectroscopy observation showed that the size of 
Gal-PEI-DNA complexes was found to increase with increas-
ing galactosylation. Cell toxicity was also found to diminish 
with increasing galactosylation. However, the transfection 
efﬁ  ciency was slightly increased in HepG2 cells.
In order to target c-myc AS-ODNs on human hepatocel-
lular carcinoma cell line Bel-7402, Jiang and Zhang (2004) 
developed Gal-PEI delivery vector with improved transfec-
tion efﬁ  ciency. In their study, Gal-PEI-c-myc AS-ODN 
showed high targeting delivery effect on Bel-7402 cells, 
which enhances the intercellular concentration of c-myc 
AS-ODN effectively, but it had no such effects on U937 and 
Raji cells. The use of PEI as gene carrier is, however, limited 
due to cytotoxicity and nonspeciﬁ  c interactions with serum 
proteins. To overcome these bottlenecks, PEI was coupled 
with poly(vinyl pyrrolidone) (PVP) as hydrophilic group 
to reduce cytotoxicity and lactose bearing galactose group 
for hepatocyte targeting. The galactosylated-PEI-graft-PVP 
(GPP) complexes showed good DNA binding capacity and 
efﬁ  ciently protect DNA from nuclease attack. The GPP also 
exhibited good transfection efﬁ  ciency in HepG2 cells, and 
displayed low cytotoxicity. These results establish the poten-
tial of sugar anchored cationic polymers. The surface prop-
erty of cytotoxic polymer like PLL and PEI can be modiﬁ  ed 
using lactoferrin and galactose, to improve their transfection 
efﬁ  ciency speciﬁ  cally to liver parenchymal cells.
Chitosan
Among the large number of cationic polymers known, 
chitosan is shown to be an effective vector that is able to 
condense and deliver DNA in vitro and in vivo. Chitosan 
is a naturally occurring linear polysaccharide consisting of 
β-(1,4) linked D-glucosamine and N-acetyl-D-glucosamine 
and produced by deacetylation of chitin (Felt et al 1998; Illum International Journal of Nanomedicine 2008:3(1) 40
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1998). It is a nontoxic, positively charged biodegradable and 
biocompatible polymer. Though, the use of chitosan as gene 
carrier is limited due to the low transfection efﬁ  ciency and 
difﬁ  culty in transfecting into a variety of cell types, especially 
the hepatoma cells, researchers have tried to improve the 
transfection efﬁ  ciency of chitosan to target hepatocytes. Park 
and coworkers (2000) described the coupling of lactobionic 
acid (bearing galactose unit) to chitosan for generating liver 
specificity and dextran was grafted on to galactosyalted 
chitosan (GC) for increasing its water solubility. As compared 
with the GC/DNA complexes, the stability of the galactosylated 
chitosan – graft – dextran (GCD/DNA) complexes was much 
higher and the GCD/DNA complexes transfected into Chang 
liver cells and that of Hep G2 cells possessing ASGP-R, 
indicative of speciﬁ  c interactions between ASGP-R on the 
cell surface and galactose ligands on chitosan. They also 
explored galactosylated chitosan (GC)-graft-poly(ethylene 
glycol) (PEG) (GCP) as a promising gene carrier and found 
that GCP/DNA complexes were effective in transfection 
experiments into Hep G2 cells and could provide protection to 
DNA from enzymatic degradation (Park et al 2001). However, 
the transfection efﬁ  ciency of both the carriers was found to be 
lower than that of lipofection.
In an alternative strategy, poly(vinyl pyrrolidone) (PVP) 
(10 and 50KDa), an amphipathic polymer with properties 
similar to PEG except having a better retention in blood, 
were conjugated with galactosylated chitosan. The binding 
strength of GC-graft-PVP (GCPVP) 10K/DNA complexes 
measured by ethidium bromide binding assay was found to 
be superior to that of the GCPVP 50K/DNA, probably attrib-
uted to its higher ﬂ  exibility due to the smaller size, whereas 
the DNAse I protection of GCPVP 10K/DNA complex was 
inferior to that of the GCPVP 50K/DNA. This indicated that 
effective complex formation required both higher binding 
strength and minimal molecular weight of polycation enough 
to induce the condensation of DNA (Park et al 2003). Gao 
and coworkers (2003) coupled, lactobionic acid (LA) bearing 
galactose group with LMWC for liver-speciﬁ  city. In their 
experiment, a series of galactosylated-LMWC (Gal-LMWC) 
samples covering a range of galactose group contents were 
prepared and used to transfer pSV-β-galactosidase reporter 
gene into HepG2, L-02, SMMC-7721, and human cervix 
adenocarcinoma (HeLa) cell lines in vitro. Gal-LMWC/DNA 
complex showed a very efﬁ  cient cell selective transfection 
to hepatocyte. The transfection efﬁ  ciency of Gal-LMWCs 
increased with the degree of the galactosylation. Cytotoxicity 
of Gal-LMWC was determined by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay and the 
results showed that the modiﬁ  ed chitosan has relatively low 
cytotoxicity, giving the evidence that the modiﬁ  ed chitosan 
vector has the potential to be used as a safe gene-delivery 
system. Similarly, LA bearing galactose group was coupled 
with water soluble chitosan (WSC) for hepatocyte speciﬁ  c-
ity. The transfection efﬁ  ciency into HepG2, which possesses 
ASGP-R, was higher than that recorded in case of HeLa 
without ASGP-R (Kim et al 2004).
Little is known on the use of chitosan for the delivery of 
AS-ODNs. Most of the cationic polymers being studied for 
gene delivery are too large and their surface charge density 
is too high to deliver AS-ODNs. Their complexation with 
AS-ODNs is a difﬁ  cult problem because of the large differ-
ence between the sizes of the two macromolecules. Due to 
their high surface charge density, the complexes of cationic 
polymers with AS-ODNs are so stable that they are taken 
up by the cells without releasing the AS-ODNs, which are, 
therefore, unable to show the antisense activity. However, 
galactosylated low molecular weight chitosan (Gal-LMWC) 
with low surface charge density may be probably suitable for 
the speciﬁ  c delivery of AS-ODNs in vitro and in vivo. Gao 
and coworkers (2005) have demonstrated that Gal-LMWC 
can be used not only as the vector for plasmid DNA, but also 
as the vector for AS-ODNs in HepG2 cells. Results showed 
that Gal-LMWC could form stable nano-complexes with 
plasmid DNA or AS-ODNs by the electrostatic interactions. 
Transfection efﬁ  ciency of Gal-LMWC/ASO complexes or 
Gal-LMWC/plasmid DNA complexes largely depends on the 
N/P ratio (Figure 5). The results of inhibition experiments fur-
ther conﬁ  rmed that the enhanced transfection efﬁ  ciency was 
due to the ASGR mediated endocytosis of the gal-LMWC/
ASO complexes or Gal- LMWC/plasmid DNA complexes. 
The resulting complexes were also found to possess low 
cytotoxicity (Figure 6).
Furthermore, in order to improve transfection effi-
ciency of water soluble chitosan, lactobionic acid bearing 
galactose group was coupled for liver speciﬁ  city and PEI 
was conjugated to galactosylated chitosan (GC) / DNA 
complexes to enhance the transfection efﬁ  ciency via proton 
sponge effect (Kim et al 2005). Initially, the effect of PEI 
on the transfection efﬁ  ciency of WSC/DNA complex was 
studied in HeLa, A549 and 293T cells, and baﬁ  lomycin A1 
was used to ascertain the mechanism of synergistic effect. 
The conjugation of PEI with WSC/DNA and GC/DNA 
complexes dramatically increased the luciferase expression 
by 10- to 1000-fold in various cell lines, and the synergistic 
effect was proved to be induced by proton sponge effect of 
PEI. The transfection of GC/DNA complexes in HepG2 was International Journal of Nanomedicine 2008:3(1) 41
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Figure 5 N/P ratio dependent transfection efﬁ  ciency of gal-LMWC/plasmid DNA complexes (a) and gal-LMWC/ASO complexes (b) in HepG2 cell line (Adapted from Gao 
et al 2005).
Figure 6 MTT assay for cytotoxicity of CaP, Lipofectin, HMWC, LMWC, and gal-LMWC in HepG2 cell line (Adapted from Gao et al 2005).
(a) (b)International Journal of Nanomedicine 2008:3(1) 42
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much higher than that of WSC/DNA even after conjugation 
with PEI, and was signiﬁ  cantly inhibited in the presence 
of galactose. However, transfection efﬁ  ciency decreased 
in the presence of baﬁ  lomycin A1, a speciﬁ  c inhibitor of 
vacuolar type H+ by inhibiting endo-/lysosomal proton pump 
(Figure 7). Cytotoxicity of PEI was also signiﬁ  cantly reduced 
by conjugation with GC/DNA complex. Very recently, Satoh 
and coworkers (2007) proposed in vitro gene delivery to 
HepG2 cells using galactosylated 6-amino-6-deoxychitosan 
as a DNA carrier. In their study a series of galactose-modiﬁ  ed 
6-amino-6-deoxy chitosan (Gal-6ACT) with degrees of sub-
stitution ranging from 3% to 50% per pyranose were prepared 
by reductive alkylation with lactose. A signiﬁ  cant increase 
in transfection efﬁ  ciency was observed at degree of substi-
tutions ranging from 18%–50% and at N/P values ranging 
from 1.5–2.5, and Gal-6ACT was found to be ∼10 times more 
efﬁ  cient than 6ACT. Interestingly, Gal-6ACT with a degree 
of substation of 38% also efﬁ  ciently transfect both A549 
and HeLa cells lacking the galactose receptor. These results 
suggest that the enhancement of transfection efﬁ  ciency of 
Gal-6ACT was not due to the increase of receptor-mediated 
cellular uptake. Thus the sugar modiﬁ  cation signiﬁ  cantly 
improves the transfection efﬁ  ciency of chitosan.
Other polycation based nanocarriers have also been inves-
tigated for hepatocytes speciﬁ  c gene delivery (Table 1).
Phosphorous-containing polymer
Phosphorus-containing polymeric gene carriers have also 
been reported to enhance transfection efﬁ  ciency. In one of 
such reports, a series of cationic polymers, polyphosphorami-
dates (PPAs), with an identical backbone, same side chain 
spacer, similar molecular weights but different charge groups 
containing primary to quaternary amino groups have been 
synthesized (Wang et al 2004). These PPAs did not show 
signiﬁ  cant capacity to buffer endosomes within pH 5−7, 
even though transfection mediated by PPA-EA seemed to 
be limited by endolysomal escape. Results showed that 
endocytosis of DNA mediated by PPAs was also similar 
(17%−22%) for all four PPAs. However, the transfec-
tion efﬁ  ciency of these PPAs varied signiﬁ  cantly. In vitro 
transfection efﬁ  ciency of PPAs decreased in the order of 
PPA-EAPPA-MEAPPA-DMA∼PPA-TMA. As shown 
in Scheme 1, Zhang and coworkers (2005) prepared galac-
tosylated polyphosphoramidates nanoparticles (Gal-PPAs) 
with varied degrees of ligand substitution (6.5%, 12.5%, 
and 21.8%) with an aim to transfer DNA in liver cells. It 
Figure 7 Effect of baﬁ  lomycin A1 on the gene transfection in 293 T cells. WSC/DNA complex was prepared at charge ratio 10 and the amount of PEI used was 0.5 Ag. Different 
amounts of baﬁ  lomycin A1 diluted in  DMSO were put into the wells.  After 10 min incubation period, transfection solutions were added into the wells.   The cells were incubated 
in the transfection solution for 4 h and then in the growth medium for 48 h (Adapted from Kim et al 2005).International Journal of Nanomedicine 2008:3(1) 43
Nano-vectors for efﬁ  cient liver speciﬁ  c gene transfer
Table 1 Studies performed with various nanocarriers for hepatocytes speciﬁ  c gene delivery
Engineered constructs Purpose/result Reference
Gal-PEG-grafted PLL 
polymeric gene carrier
•   Form stable and soluble complexes with nucleic acids (which in turn are able to efﬁ  ciently 
transform cells)
•   PEG attached to the PLL gives better solubility to the carrier complex and improved trans-
fection efﬁ  ciency without considerable cytotoxicity.
United States Patent 
6177274
Lactosylated PLL •   The transfection efﬁ  ciency of HepG2 cells with pSV2Luc/lactosylated PLL complexes was 
greatly enhanced in the presence of chloroquine/fusogenic peptide.
•   In the presence of the fusogenic peptide, the luciferase activity in HepG2 cells was 10 fold 
larger than that of cells transfected with pSV2Luc/lactosylated PLL complexes in the pres-
ence of chloroquine.
Midoux et al (1993)
Asialofetuin-PLL conjugate •  Asialofetuin-PLL conjugate efﬁ  ciently internalize ODN in hepatoma cell line PLC/PRF/5. Reinis et al (1993)
[(Gal-6)3Lys2-bA] for 
hepatocytes targeting 
•   Trigalactosylated bisacridine [(Gal-6)3Lys2-bA] compound could mediate the binding of 
DNA to both the ricin lectin and to primary hepatocytes. 
Haensler and szoka 
(1993)
Nonenzymatic glycosylation 
of poly-l-lysine
•   PLL was crosslinked to an asialoglycoprotein, and the resulting conjugate was complexed 
with the DNA.
•   The electrostatic binding between DNA and PLL asialoglycoprotein ensures efﬁ  cient i.v. 
delivery complex to the liver by receptor mediated endocytosis.
Martinez-Fong et al 
(1994)
DNA/lactosylated polylysine 
complexes
•   At high concentrations of chloroquine induced the dissociation of plasmid DNA/lactosyl-
ated PLL complexes and enhanced the transfection.
•   The luciferase activity was enhanced in the presence of primaquine, a chloroquine analogue, 
but was not increased when transfection was performed in the presence of ammonium 
chloride, methylamine, spermine, or monensin, compounds known to neutralize the pH of 
the endocytotic vesicle lumen as chloroquine does.
Erbacher et al (1996)
Lactose-PEG-grafted PLL •   Transfection experiments showed that Lac-PEG-PLL efﬁ  ciently delivers DNA to a hepatoma 
cell line in vitro (at a 1:3 weight ratio of DNA to carrier).
•   As the lactose-PEG substitution content increased up to 30%, the transfection efﬁ  ciency 
increased, which demonstrated that the lactose serves as a targeting moiety. No consider-
able cytotoxicity was observed due to Lac-PEG-PLL. The use of chloroquine increased 
transfection efﬁ  ciency that indicated the involvement of hydrolytic degradation of the 
system in lysosome.
Choi et al (1998)
PLL/DNA polyplexes •   Attachment of asialoorosomucoid to PLL increased the PLL chain length required for 
efﬁ  cient DNA binding in saline and for efﬁ  cient DNA condensation.
•   Attachment of asialoorosomucoid\lessened, but did not eliminate, the aggregation of PLL 
polyplexes, and did not result in efﬁ  cient delivery of polyplexes to hepatocytes.
•   Conjugation of PEG to PLL sterically stabilized resulting polyplexes at neutral charge ratios 
by shielding the surfaces.
Kwoh et al (1999)
Lactose-PEG grafted PLL •   Lac-PEG-PLL was shown to protect DNA against nuclease action in a DNase I protection 
assay.
•   Lac-PEG-PLI, formed complexes with plasmid DNA gave little cytotoxicity, and showed 
increased efﬁ  ciency of gene transfer into hepatoma cells in vitro.
•   Lac-PEG-PLL was more efﬁ  cient than Lipofectin or galactose-PEG-PLL in transfection 
efﬁ  ciency.
Choi et al (1999)
Galactosylated PEI/DNA 
complexes
•   5% of the PEI nitrogens were grafted with a linear tetragalactose structure (lGal4), small and 
stable particles were formed upon complexation with plasmid DNA.
•   Slightly charged PEI-lGal4/DNA complexes were very selectively galactosylated-PEI vector 
to transfect hepatocytes.
Bettinger el al (1999)
Glycosylated-PEI  •   Gal-PEI was prepared using titanium (IV) isopropoxide and sodium borohydride, as a substi-
tute for the highly toxic sodium cyanoborohydride method.
•  Systems were found to be nontoxic and efﬁ  cient transfection agent in HepG2 cells.
Leclercq et al (2000)
Poly(2-(dimethylamino)ethyl 
methacrylate - N-vinyl-
2-pyrrolidone (DMAEMA-
NVP)-b-PEG-galactose as 
gene delivery vector for 
hepatocytes
•   Poly(DMAEMA-NVP)-b-PEG-galactose in combination with an endosomolytic peptide, 
KALA demonstrated sufﬁ  cient transfection efﬁ  ciency as high as that of commercial agent.
Lim et al (2000)
Pullulan derivatives with che-
late residues based on metal 
coordination
•   i.v. injection of the pullulan derivatives-plasmid DNA conjugates with Zn2+ coordination 
signiﬁ  cantly enhanced the level of gene expression in the liver.
•   A ﬂ  uorescent-microscopic study revealed that the plasmid DNA was localized at the liver 
after injection of the pullulan-DTPA-plasmid DNA conjugate with Zn2+ coordination.
Hosseinkhni et al 
(2002)
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was found that as galactose substitution increases, in vitro 
cytotoxicity of Gal-PPA decreases. Furthermore, binary and 
ternary nanoparticles of galactosylated PPA/DNA were pre-
pared and used in transfection studies (Scheme 2). The results 
of this study revealed that in HepG2 cells and primary rat 
hepatocytes, the transfection efﬁ  ciency mediated by ternary 
nanoparticles prepared with 6.5% Gal-PPA was 6–7200 
times higher than PPA-dipropylenetriamine (DPA)/DNA 
nanoparticles.
Recently, in a slightly different approach, Horiuchi and 
coworkers (2006) investigated and compared the transfection 
properties of nonglycosilated, singly and triply lactose-
functionalized derivatives of calix[4]resorcarene-based 
amphiphilic octaamine. They all bind to luciferase-encoding 
pDNA and transfection of HeLa and HepG2 cell lines 
showed decreasing expression efﬁ  ciency and cytotoxicity 
with increasing number of lactose moieties. However, cell 
selectivity for HepG2 over HeLa increased with increasing 
the number of lactose residues. Concisely, the lactose 
moieties introduced were found to be charge-masking, 
aggregation-promoting, and toxicity-lowering.
Lysosome disruptive elements to target 
hepatocyte
It is well known that the transfection ability of nonviral 
gene delivery vectors is generally hampered by lysosomal 
degradation of the internalized DNA. Current vectors that 
enable the endo-lysosomal escape of macromolecules (ie, 
DNA, siRNA) are limited by their toxicity and by their 
ability to carry only limited classes of therapeutic agents. In 
an attempt to facilitate the escape of DNA from lysosomal 
compartment and enhancing the transfection efﬁ  ciency in a 
cell-speciﬁ  c fashion, Van Rossenberg and coworkers (2002) 
developed a nontoxic cell specific lysosome disruptive 
Table 1 (Continued)
Galactose-PEI-DNA •   MTT and LDH assay conﬁ  rmed that cytotoxicity of gal-PEI was found to decrease with 
increasing galactosylation.
•   Require necessity of careful optimization of polyplex composition for active gene targeting.
Kunath et al (2003)
Lactose-appended schizo-
phyllan
•   Schizophyllan (beta-1,3-glucan) derivative carrying lactose-appendages prepared by reduc-
tive amination, effectively mediates gene transfection into hepatocytes.
Hasegawa et al 
(2004)
Surface modiﬁ  ed albumin 
nanoparticles
•   In this study, Calcein loaded bovine serum albumin nanoparticle (Cal-BSA-NP) and bovine 
serum albumin nanoparticles with their surface modiﬁ  ed by glycyrrhizin (Cal-BSA-NP-GL) 
were developed as a novel hepatocyte targeting based on active targeting technology medi-
ated by speciﬁ  c binding site of GL on rat cellular membrane.
•   The uptake amount of Cal-BSA-NP-GL by rat hepatocytes was 4.43-fold higher than that of 
Cal-BSA-NP and results shows signiﬁ  cant difference in the uptake of Cal-BSA-NP-GL and 
Cal-BSA-NP by hepatocytes.
Mao et al (2005)
β-(1–3)-D-glucan schizophyl-
lan for AS-ODN delivery
•   Galactose moieties were conjugated to the side chain of SPG to enhance cellular ingestion 
through endocytosis mediated by ASGP-Rs. 
Karinaga et al (2006)
Chitosan-DNA nanoparticles •   Chitosan-DNA nanoparticles showed several times higher luciferase expression in the liver 
after retrograde intrabiliary infusion (RII).
•   Luciferase expression by RII of PEI-DNA nanoparticles was 17-fold lower than that of 
chitosan-DNA nanoparticles.
•  RII of chitosan-DNA nanoparticles did not yield signiﬁ  cant toxicity.
Dai et al (2006)
Surface modiﬁ  ed magnetite 
nanoparticles
•   In this report, superparamagnetic magnetite nanoparticles were surface-modiﬁ  ed with 
lactobionic acid (LA) to improve their intracellular uptake and ability to target hepatocytes.
•   Cell culture experiment showed that LA-modiﬁ  ed nanoparticles were internalized into 
hepatocytes and atomic absorption spectrometer (AAS) measurement indicated that the 
uptake amount of LA-modiﬁ  ed magnetite into hepatocytes was higher than that of unmodi-
ﬁ  ed and control MA-modiﬁ  ed nanoparticles.
•   LA-modiﬁ  ed nanoparticle solution was injected in rabbit and the magnetic resonance (MR) 
images obtained showed that LA-coated nanoparticles were selectively accumulated onto 
the hepatocytes
Kamruzzaman et al 
(2007)
Synthetic PEGylated gly-
coproteins for hepatocyte 
targeting
•   PEGylated glycoproteins (PGPs) were synthesized by copolymerizing a Cys-terminated 
PEG-peptide, glycopeptide, and melittin peptide by varying the ratio of PEG-peptide 
(20%–90%) and melittin (0%–70%) with a constant amount of glycopeptide (10%).
•   Results shows that the level of gene expression mediated by PGP-DNA was 5000-fold less 
than direct hydrodynamic dosing of an equivalent amount of DNA and was independent of 
the mol percent of melittin incorporated into the polymer, but dependent on the presence 
of galactose on PGP.
Chen et al (2007)
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element for hepatocyte specific gene transfer. In their 
experiment, two fusogenic peptides (INF7 and JTS-1) were 
tested for their capacity to disrupt lysosomes. INF7, a 23-mer 
peptide is derived from hemagglutinin (HA), and JTS-1, an 
artiﬁ  cial INF7 mimic designed for pH-sensitive helix forma-
tion, were studied. INF7 was selected for coupling to a high 
afﬁ  nity ligand for the ASGP-R, and K(GalNAc)2 to improve 
its uptake by liver parenchymal cells. Results showed that 
the parent peptide disrupted both cholesterol-rich and poor 
liposomes, while INF7-K(GalNAc)2, only induced leakage 
of cholesterol-poor liposomes only, making it eminently 
suitable for targeted fusogenic activity in parenchymal cells. 
The endosomal membrane of eukaryotic cells is known to 
contain 5% cholesterol, this implies that the conjugate 
displays a higher selectivity toward endosomal membranes. 
Although both INF7 and INF7-K(GalNAc)2 were found to 
increase the transfection efﬁ  ciency of polyplex-mediated 
gene transfer to parenchymal liver cells by 30-fold, only 
INF7-K(GalNAc)2 appeared to do so in an ASGP-R speciﬁ  c 
manner. In vivo, INF7-K(GalNAc)2 was speciﬁ  cally targeted 
to the mice liver, whereas INF7 was distributed evenly over 
various organs. In another study, Panyam and coworkers 
(2002) reported rapid (10 min) endo-lysosomal escape 
of biodegradable nanoparticles (NPs) formulated from the 
copolymers of poly(DL-lactide-co-glycolide) (PLGA) and 
proposed that the mechanism of rapid escape is by selec-
tive reversal of the surface charge of NPs (from anionic to 
cationic) in the acidic endo-lysosomal compartment, which 
causes the NPs to interact with the endo-lysosomal membrane 
and escape into the cytosol.
Bio-nanocapsules for hepatocyte speciﬁ  c 
gene transfer
Recently, bio-nanocapsules (BNCs) have been demonstrated 
as efﬁ  cient delivery vectors speciﬁ  cally targeting human 
hepatocytes (Nagaoka et al 2007). BNCs are composed of the 
recombinant envelope L-protein of hepatitis B virus. Previ-
ously, envelop proteins have been developed as vaccine for 
hepatitis B. The envelope of HBV is composed mainly of 
three closely related surface proteins that are known as the 
large (L), the middle (M) and the small (S) proteins. They 
are encoded in one open reading frame of HBV genome 
Scheme 1 Synthetic scheme for PPA-DPA and galactosylated PPA-DPA (adapted from Zhang and coworker 2005).International Journal of Nanomedicine 2008:3(1) 46
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translated from three different in-frame initiation sites. When 
these proteins were expressed, each S-, M- and L-protein was 
found to form hollow virus-like nanoparticles. The particle 
composed of L-protein showed, in particular, a speciﬁ  c 
afﬁ  nity to human hepatocytes due to the hepatocyte recogni-
tion site localized in the amino terminus. For the purpose of 
developing safe and efﬁ  cient delivery systems, vectors hav-
ing a targeting potential for speciﬁ  c cells or tissues, Nagaoka 
and coworkers (2007) exploited the nanoparticles composed 
of recombinant envelope protein as bio-nanocapsule (BNC) 
prepared from mammalian cells or yeast cells. However, 
aggregation of envelope proteins in the BNCs may occur 
during long-term storage, which might be attributed to the 
false disulﬁ  de bridges and which could be overcome by the 
cysteine residues in the L-protein.
Stability of nano-vectors
The stability of nanoparticulate systems poses a serious chal-
lenge in gene/drug delivery research. Nanoparticle dispersion 
is a typical thermodynamically unstable system due to its large 
speciﬁ  c interfacial area. During storage, particle aggregation 
often occurs. Some efforts have been made towards increasing 
the physical stability of such a system. Lyophilization is one 
such technique used for this purpose. However, lyophilization 
has some disadvantages (particle size increases during the 
process of freeze drying and lyophilized nanoparticles may 
still aggregate after some time on storage).
The incorporation of various site directing molecules on 
nano-vectors confers them suitable stability in bio-ﬂ  uids as 
well as site-speciﬁ  city towards receptors. However, in some 
cases, ligands provide only stability and better structure 
Scheme 2 Preparation of binary and ternary nanoparticles containing galactosylated PPA-DPA (adapted from Zhang and coworker2005).International Journal of Nanomedicine 2008:3(1) 47
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integrity against harsh bio-environments encountered after 
oral/parenteral drug administration. Sunamoto and Iwamaoto 
(1986), and Sihorkar and Vyas (2001) reviewed stability 
issues of liposomal carrier systems. Unfortunately, majority 
of the experiments described were performed in vitro only and 
lack in in vivo data to correlate and interpretate the results.
Conclusions
Hepatocytes (the principal parenchymal cells of the liver) 
are a much sought-after target of gene therapy, because 
they play many unique roles in the physiology of the 
mammalian host. The liver poses formidable obstacles to 
hepatocyte-speciﬁ  c gene delivery. Many pharmaceutical 
nanocarriers that effectively deliver genes to other cell 
types do not efﬁ  ciently target the hepatocyte. Advances 
in nanotechnology and cell biology provided new 
opportunities for drug/gene delivery research to focus 
hepatocyte by receptor mediated endocytosis. Several 
glycosylated nanocarriers have been developed and paved 
the way for biologically safe, site-speciﬁ  c and stable 
transgene expression. In past few years, receptor mediated 
cellular bioevents have received major attention in modern 
drug/gene delivery therapeutics, albeit the approach is 
just at nascent stage, it shows a promise in near future 
to develop DNA based pharmaceuticals for the effective 
managements of liver associated disorders.
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